3-Benzyl-8-(6-chloropyridazin-3-yl)-3,8-diazabicyclo[4.3.1]decane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Benzyl-8-(6-chloropyridazin-3-yl)-3,8-diazabicyclo[4.3.1]decane
• 化学式: C₁₉H₂₃ClN₄
• 分子量: 342.9
• InChiKey: ZYZYDFVOVNJUNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Novel heteroaryl-diazabicyclo alkanes as cns-modulators
  申请人：——

  公开号：US20040147505A1

  公开（公告）日：2004-07-29

  The present invention relates to novel diazabicycloalkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. A diazabicycloalkane derivative selected from those represented by Formula I, by Formula II, by Formula III, by Formula IV, and by Formula V. 1

  本发明涉及新型的二氮杂双环烷衍生物，发现其在尼古丁酸乙酰胆碱受体上是胆碱能配体，并且是单胺类受体和转运体的调节剂。由于其药理学特性，该发明的化合物可用于治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或疾患、内分泌疾病或疾患、神经退行性疾病或疾患、炎症相关的疾病或疾患、疼痛以及由于滥用化学物质而引起的戒断症状等各种疾病或疾患。选择由式I、式II、式III、式IV和式V.1所代表的二氮杂双环烷衍生物。
• NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS
  申请人：NeuroSearch A/S

  公开号：EP1397365A1

  公开（公告）日：2004-03-17
• HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS
  申请人：NeuroSearch A/S

  公开号：EP1397365B1

  公开（公告）日：2005-02-16
• [EN] NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS<br/>[FR] NOUVEAUX HETEROARYL-DIAZABICYCLO-ALCANES A TITRE DE MODULATEURS DU SNC
  申请人：NEUROSEARCH AS

  公开号：WO2002096911A1

  公开（公告）日：2002-12-05

  The present invention relates to novel diazabicycloalkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. A diazabicycloalkane derivative selected from those represented by Formula I, by Formula II, by Formula III, by Formula IV, and by Formula V.